Seres Therapeutics, Inc. - MCRB
About Gravity Analytica
Recent News
- 05.27.2025 - Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
- 05.27.2025 - Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
- 05.07.2025 - Q1 2025 Seres Therapeutics, Inc. Earnings Conference Call
- 05.07.2025 - Q1 2025 Seres Therapeutics, Inc. Earnings Conference Call
- 05.07.2025 - Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
- 05.07.2025 - Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
- 04.29.2025 - Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
- 04.29.2025 - Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
- 04.23.2025 - Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025
- 04.23.2025 - Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025
Recent Filings
- 05.19.2025 - 4 Statement of changes in beneficial ownership of securities
- 05.19.2025 - 4 Statement of changes in beneficial ownership of securities
- 05.19.2025 - 4 Statement of changes in beneficial ownership of securities
- 05.19.2025 - 4 Statement of changes in beneficial ownership of securities
- 05.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
- 05.07.2025 - S-8 Securities to be offered to employees in employee benefit plans
- 05.07.2025 - EX-99.1 EX-99.1
- 05.07.2025 - 8-K Current report
- 04.22.2025 - 8-K Current report
- 04.14.2025 - 8-K Current report